CARLSBAD, Calif., Dec. 2 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today announced the Company's participation at the RBC Capital Markets 2008 Healthcare Conference scheduled to take place at the Westin New York Hotel at Times Square on December 10-11, 2008.
Sam Riccitelli, COO and executive vice president of Genoptix, will take part in a panel discussion at the conference on Wednesday, December 10, beginning at approximately 12:30 p.m. EST. Mr. Riccitelli will provide an overview of the Company's specialized diagnostic laboratory service offerings, growth strategies and past operational performance.
The panel discussion on personalized medicine is expected to last approximately 55 minutes, including an audience Q&A session, and will be web cast live and made accessible through the investor relations section of the Genoptix website at www.genoptix.com. Those who would like to listen to the presentation should go to this site at least 15 minutes prior to the event to register, download and install any necessary software. A replay will also be available for 30 days following the initial presentation web cast.
About Genoptix, Inc.
Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma.Founded in 1999, Genoptix completed its initial public offering in November 2007 and is headquartered in Carlsbad, California. For more information, please visit www.genoptix.com.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Genoptix disclaims, however, any intent or obligation to update these forward-looking statements.
|SOURCE Genoptix, Inc.|
Copyright©2008 PR Newswire.
All rights reserved